Last viewed:
SYRS
Prices are updated after-hours
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
(0.0% 1d)
(-19.3% 1m)
(95.8% 1y)
(0.0% 2d)
(0.0% 3d)
(-4.5% 7d)
(-56.13%
volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 28,509,894
http://www.syros.com
Sec
Filling
|
Patents
| 83 employees
(US) Syros Pharmaceuticals, Inc. engages in the development of gene control therapies for cancer and diseases. Its product candidates include SY-1425 and SY-5609. The company was founded by Richard A. Young, Nathanael S. Gray, and James E. Bradner on November 9, 2011 and is headquartered in Cambridge, MA.
cancer
add to watch list
Paper trade
email alert is off
Press-releases
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
Published: 2024-04-09
(Crawled : 12:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| 10.13%
| O: 2.16%
H: 23.21%
C: 16.03%
fda
treatment
designation
for
aml
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-03-27
(Crawled : 00:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| -18.24%
| O: -4.8%
H: 3.7%
C: -1.85%
year
update
financial
results
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
Published: 2024-03-25
(Crawled : 15:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| -18.5%
| O: -0.32%
H: 3.84%
C: 2.4%
trial
Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Published: 2024-03-20
(Crawled : 12:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| -17.98%
| O: 0.32%
H: 2.08%
C: 1.28%
report
year
financial
results
Syros to Participate in TD Cowen 44th Annual Health Care Conference
Published: 2024-02-27
(Crawled : 13:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| -31.78%
| O: 1.07%
H: 5.15%
C: -3.04%
conference
health
care
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
Published: 2023-12-19
(Crawled : 14:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| 18.84%
| O: 2.56%
H: 28.34%
C: 27.66%
offering
Syros Announces Encouraging Initial Data from Randomized SELECT-AML-1 Phase 2 Clinical Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine
Published: 2023-12-06
(Crawled : 15:30)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| 81.21%
| O: 2.13%
H: 61.11%
C: 39.58%
trial
Syros to Participate in Upcoming Investor Conferences - November 21, 2023
Published: 2023-11-21
(Crawled : 19:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| 78.05%
| O: -2.09%
H: 6.05%
C: 3.2%
Syros Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
Published: 2023-11-14
(Crawled : 15:30)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| 89.96%
| O: -5.2%
H: 6.67%
C: 6.67%
update
financial
results
Syros to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
Published: 2023-11-07
(Crawled : 14:00)
- biospace.com/
SYRS
|
$4.525
-4.13%
50K
|
Health Technology
| 82.5%
| O: 2.14%
H: 4.55%
C: 3.15%
report
financial
results
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0000950170-24-040302
4
2024-04-02
2024-03-31
Sell
M
13333
26667
0000950170-24-040302
4
2024-04-02
2024-03-31
Sell
M
2000
4000
0000950170-24-040302
4
2024-04-02
2024-04-02
Sell
S
150
10451
0000950170-24-040302
4
2024-04-02
2024-04-01
Sell
F
4732
10601
0000950170-24-040302
4
2024-04-02
2024-03-31
Buy
M
13333
15333
0000950170-24-040302
4
2024-04-02
2024-03-31
Buy
M
2000
2000
0000950170-24-040297
4
2024-04-02
2024-03-27
Sell
M
22500
0
0000950170-24-040297
4
2024-04-02
2024-03-28
Sell
F
7046
39757
0000950170-24-040297
4
2024-04-02
2024-03-27
Buy
M
22500
46803